The comparison of metformin, pioglitazon and Silymarin on biochemical indices

The comparison of metformin, pioglitazon and Silymarin on biochemical indices in patient with nonalcoholic fatty liver

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201105084849N2

Enrollment

Registered

2011-05-28

Start date

2010-11-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nutritional and metabolic disorders in diseases classified elsewhere. Nutritional and metabolic disorders in diseases classified elsewhere

Interventions

Intervention 1: administration of 500mg metformin daily for 2 months. Intervention 2: administration of 15mg pioglitazone daily for 2 months. Intervention 3: administration of 140mg silymarin daily fo

Treatment - Drugs

administration of 500mg metformin daily for 2 months

administration of 15mg pioglitazone daily for 2 months

administration of 140mg silymarin daily for 2 months

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: inclusion criteria; patients with NASH; rising of AST and ALT; evidence of fatty liver in ultrasound and exclusion criteria; DM; Alchole drinking; HBS Ag; HCV Ab

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
FBS. Timepoint: 2 months after first measuring. Method of measurement: blood sampling.	—

Secondary

Measure	Time frame
ALT. Timepoint: 2 months after first measuring. Method of measurement: blood sampling.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHoma Masroor

Qazvin University of Medical Science

hshole@yahoo.com+98 912 215 5438

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026